An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)
Clinical Trial Grant
Awarded By
Henlius USA Inc.
Start Date
October 13, 2025
End Date
October 12, 2030
Awarded By
Henlius USA Inc.
Start Date
October 13, 2025
End Date
October 12, 2030